文献类型：期刊文献

中文题名：利拉鲁肽注射液联合二甲双胍缓释片治疗肥胖2型糖尿病患者的临床研究

英文题名：Clinical trial of liraglutide injection combined with metformin sustained-release tablets in the treatment of obese type 2 diabetes

作者：鲍洪雅[1];王志英[1];朱巍[2]

机构：[1]绍兴文理学院附属医院综合内科,浙江绍兴312000;[2]绍兴文理学院附属医院内分泌科,浙江绍兴312000

年份：2021

卷号：37

期号：8

起止页码：952

中文期刊名：中国临床药理学杂志

外文期刊名：The Chinese Journal of Clinical Pharmacology

收录：CSTPCD、、CSCD2021_2022、北大核心、CSCD、北大核心2020

语种：中文

中文关键词：利拉鲁肽注射液;二甲双胍缓释片;2型糖尿病;肥胖

外文关键词：liraglutide injection;metformin sustained-release tablet;type 2 diabetes;obesity

中文摘要：目的观察利拉鲁肽注射液联合二甲双胍缓释片治疗肥胖合并2型糖尿病患者的临床疗效和安全性。方法将我院收治的192例肥胖2型糖尿病患者随机分为对照组和试验组,各组96例。对照组给予二甲双胍每次1.0 g,bid,口服;试验组在对照组基础上给予利拉鲁肽0.6 mg·d^(-1),1周后改为1.2 mg·d^(-1),皮下注射。比较2组患者临床疗效、治疗前后体重指数(BMI)和糖化血红蛋白(HAb1c)、血清肝酶、人成纤维细胞生长因子21(FGF21)、胰岛素样生长因子(IGF)水平以及治疗期间药物不良反应发生率。结果治疗后,试验组和对照组的总有效率分为别为93.75%(90例/96例)和81.25%(78例/96例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的BMI分别为(24.71±1.55)和(25.63±2.71)kg·m^(-2);HbA1c分别为(5.61±0.51)%和(7.03±0.45)%;谷丙转氨酶(GPT)分别为(14.54±0.92)和(18.51±0.88)U·L^(-1);谷草转氨酶(GOT)分别为(16.33±1.18)和(19.46±0.86)U·L^(-1);谷氨酰转肽酶(GGT)分别为(18.26±1.23)和(22.93±1.21)U·L^(-1);FGF21分别为(3.43±0.56)和(5.85±0.34)mmol·L^(-1);IGF分别为(165.19±3.05)和(176.16±2.13)mmol·L^(-1),差异均有统计学意义(均P<0.05)。试验组和对照组的药物不良反应发生率分别为10.42%(10例/96例)和12.50%(12例/96例),差异无统计学意义(P>0.05)。结论利拉鲁肽注射液联合二甲双胍缓释片治疗肥胖2型糖尿病患者,能有效控制体重及血糖水平,改善血清肝酶及FGF21、IGF,提高治疗的临床效果。

外文摘要：Objective To observe the clinical effect and safety of liraglutide injection combined with metformin sustained-release tablets in the treatment of obesity complicated with type 2 diabetes mellitus.Methods A total of 192 patients with type 2 diabetes were randomly divided into control group and treatment group.The control group was given metformin 1.0 g·time^(-1),twice a day,oral treatment,the treatment group was given liraglutide 0.6 mg·d^(-1) on the basis of the control group,1 week later changed to 1.2 mg·d^(-1),subcutaneous injection treatment.The clinical efficacy,body mass index(BMI),glycosylated hemoglobin,serum liver enzymes,human fibroblast growth factor 21(FGF21),insulin-like growth factor(IGF)levels before and after treatment,and the incidence of adverse reactions during treatment were compared between the two groups.Results After treatment,the total effective rates of the treatment group and the control group were 93.75%(90 cases/96 cases)and 81.25%(78 cases/96 cases),respectively,and the difference was statistically significant(P<0.05).After treatment,BMI of the treatment group and the control group were(24.71±1.55),(25.63±2.71)kg·m^(-2);Hb A1 c were(5.61±0.51)%,(7.03±0.45)%;glutamic-pyruvic transaminase(GPT)were(14.54±0.92),(18.51±0.88)U·L^(-1);glutamic-oxaloacetic transaminase(GOT)were(16.33±1.18),(19.46±0.86)U·L^(-1);glutamyl transpeptidase(GGT)were(18.26±1.23),(22.93±1.21)U·L^(-1);FGF21 were(3.43±0.56),(5.85±0.34)mmol·L^(-1);IGF were(165.19±3.05)and(176.16±2.13)mmol·L^(-1),with statistically significant difference(P<0.05).There was no significant difference in the incidence of adverse reactions between the treatment group and the control group[10.42%(10 cases/96 cases)vs 12.50%(12 cases/96 cases)](P>0.05).Conclusions Liraglutide injection combined with metformin sustained-release tablets in the treatment of obesity complicated with type 2 diabetes can effectively control the weight and blood glucose level of patients,improve the serum liver enzymes,FGF21 and IGF,and increase the clinical effect of treatment.